Newsflash
Prodotti competitors / Area HIV

Discontinuation of a paediatric development plan for the J&J candidates for prevention of human immunodeficiency virus (HIV-1) infection

  • 31 gennaio 2025
Immagine News
Attenzione! Il presente contenuto è disponibile solo in lingua originale.

EMEA-002161-PIP01-17: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

Trimeric, recombinant HIV-1 envelope glycoprotein 140 of Clade C / trimeric, recombinant HIV-1 envelope glycoprotein 140 containing motifs of multiple HIV-1 variants, adjuvanted with aluminium phosphate [Clade C gp140/ Mosaic gp140]

 

EMEA-002160-PIP01-17: Notification of discontinuation of a paediatric development which is covered by an agreed PIP Decision

serotype 26 adenovirus encoding mosaic 1 HIV-1 group-specific antigen and polymerase proteins (Ad26.Mos1.Gag-Pol)

serotype 26 adenovirus encoding mosaic 2 HIV-1 group-specific antigen and polymerase proteins (Ad26.Mos2.Gag-Pol)

serotype 26 adenovirus encoding mosaic 1 HIV-1 envelope protein (Ad26.Mos1.Env)

serotype 26 adenovirus encoding mosaic 2S HIV-1 envelope protein (Ad26.Mos2S.Env) [Ad26.Mos4.HIV]

Tags:
Grazie per il tuo feedback!